David Veesler

Dr. David Veesler received his doctoral degree from Aix Marseille University in 2010. From 2011 to 2014, he worked as a Postdoctoral Fellow at the Scripps Research Institute. Since 2015, he has been working as an Assistant Professor at the Department of Biochemistry, University of Washington. Dr. Veesler’s main research interest is to tackle the structure of macromolecular machines of biological interest to understand the mechanisms underlying their functions. His research team use a multi-disciplinary approach involving cryo-electron microscopy and X-ray crystallography complemented by various biochemical and biophysical techniques to obtain multi-scale data ranging from atom to whole-cell.

Lab Information

The Veesler Lab, Department of Biochemistry, University of Washington

Research Area and Skills

Recognize this scientist’s Expertise for their contribution in your research

SARS-CoV-2/COVID-19 0 membrane fusion activation 0 germline antibody binding to HIV envelope 0 Epstein-Barr virus inhibition 0 deltacoronavirus spike structure 0

More

  • Post
  • Publication
  • Plasmid
  • Following (0)
  • Follower (9)


This guy hasn’t posted anything yet.

Hot Posts for You

Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host. It is a key parameter to evaluate COVID-19 vaccine efficacy per Guidelines from Development and ...Learn More


This 3D animation shows you how DNA is copied in a cell. It shows how both strands of the DNA helix are unzipped and copied to produce two identical DNA molecules. TranscriptDNA is a molecule made up of two strands twisted around each other in a double helix shape. Each strand is ...Learn More


IntroductionA gleam of light finally shone down on the global crisis of the prolonged battle against COVID-19, giving people hopes of preventive care and treatment in the near future by monoclonal antibodies against SARS-CoV-2. As stated the news of NIH’s phase III clinical ...Learn More


"Those who do not know history are obliged to repeat it" This famous phrase that could be from any history teacher to his suspended students has been attributed to great figures in history such as Napoleon or the philosopher George Santayana. In a modern version of it we could say ...Learn More


In recent years there is an increasing number of cytotoxic chemotherapeutic compounds with the ability to rapidly kill dividing cancer cells in preference to non-dividing healthy cells. Nevertheless, the major drawback of chemotherapy is that, in addition to damaging the cancer ...Learn More


The coronavirus pandemic caught everyone unprepared. We had to deal with the fear of an unknown virus which can be lethal for some people. And the whole world just stopped in an attempt to prevent the virus spread.Suddenly we had to adapt to a new way of living, socially isolated ...Learn More


This is the first episode of MolecularCloud Pioneer Scientist interview series. In this interview, MolecularCloud talks with Prof. Shuo Huang from Nanjing University about the recent publications of Dr. Huang’s team and the future prospect of biological nanopore technology. The ...Learn More


The increasing number of confirmed COVID-19 cases is prompting an unprecedented global effort to find a treatment for the disease. Given the fact that a new drug development could be a decade work from initial discovery to the marketplace, scientists are racing to search a cure ...Learn More


The previous article on precision medicine was focused on Pharmacogenomics as a fundamental aspect of cancer therapeutics. In this sequel, emphasis would be on the role of immuno-oncology in personalization of cancer therapy, citing anti PD therapy as an example with hypothetical ...Learn More


  1. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. Viruses (in press).

  2. Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT and Veesler D. Cell (2020) 181(2):281-292.

  3. Parks KR, MacCamy AJ, Trichka J, Gray M, Weidle C, Borst AJ, Khechaduri A, Takushi B, Agrawal P, Guenaga J, Wyatt RT, Coler R, LaBranche C, Montefiori DC, Veesler D, Pancera M, McGuire AT and Stamatatos L. Overcoming steric restrictions of VRC01 HIV-1 neutralizing antibodies through immunization. Cell Rep. (2019) 29(10):3060-3072.

  4. Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors. Park YJ, Walls AC, Wang Z, Sauer MM, Li W, Tortorici MA, Bosch BJ, DiMaio F and Veesler D. Nat Struct Mol Biol. (2019) 26(12):1151-1157.

  5. Dang HV, Chan YP, Park YJ, Snijder J, Da Silva SC, Vu B, Yan L, Feng YR, Rockx B, Geisbert TW, Mire CE, Broder CC and Veesler D. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. Nat Struct Mol Biol. (2019) 26(10):980-987.

  6. Tortorici MA, and Veesler D. Structural insights into coronavirus entry. Advances in Virus Research. (2019) 105:93-116.

  7. Tortorici MA, Walls AC, Lang Y, Wang C, Li Z, Koerhuis D, Boons GJ, Bosch BJ, Rey FA, DeGroot RJ and Veesler D. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol. (2019) 26(6):481-489.


This guy hasn’t plasmids anything yet.

Hot plasmids


This guy has no following anyone.

Popular Cloud Scientists

Cloud Scientists

About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2024 MolecularCloud